Impact of the “Class B infectious disease Class B management” policy on the number of cases and deaths of notifiable infectious diseases in China during the COVID-19 epidemic: a nationwide interrupted time series study Authors: Yifei Ma, Shujun Xu, Yifei Ning, Jiaming Guo, Yuxin Luo, Jiantao Li, Lijian Lei, Lu He, Tong Wang, Hongmei Yu, Jun Xie Published: 2025 ABSTRACT AbstractBackgroundCurrently, the world has entered the post-COVID-19 era. Since January 8, 2023, China has implemented the “Class B infectious disease Class B management” policy, which is a major shift in China’s epidemic prevention and control measures. It is imperative to assess whether the policy will have an impact on the spread of other notifiable infectious diseases in China.MethodsThe “Class B infectious disease Class B management” policy is regarded as an intervention. We extracted monthly data on cases and deaths of the 39 notifiable infectious diseases (nine diseases are transmitted through contact, twelve through air, seven through water and food, seven through insect, and four through blood and sex) between December 2019 and May 2024 from the National Disease Control and Prevention Administration of the People’s Republic of China. Based on an interrupted time series design, we applied quasi-Poisson regression models to examine the immediate and sustained effects of the intervention on the number of cases and deaths of the 39 notifiable infectious diseases in China.ResultsDuring the intervention period from January 2023 to May 2024, the total number of cases and deaths of the 39 notifiable infectious diseases increased by 230.69% and 14.20% respectively compared to the same period had no intervention been implemented. Surprisingly, the number of dengue fever cases increased tremendously by 12,495.57%, while the number of cases of brucellosis and the number of deaths from tuberculosis and infectious diarrhea decreased rather than increased. We found a significant immediate increase in the total number of cases and deaths of the 39 notifiable infectious diseases and the number of cases of airborne and insect-borne infectious diseases at the beginning of the policy. In the long run, the policy had a significant positive sustained effect on the number of cases of blood-borne and sexual infectious diseases and a significant negative sustained effect on the number of deaths from tuberculosis.ConclusionsIf China or other regions relax their prevention and control measures against coronavirus infectious diseases similar to SARS in the future, health authorities should, on the one hand, remain vigilant immediately to prevent a sudden increase in the number of cases of airborne and insect-borne infectious diseases, and on the other hand, maintain long term close monitoring of the trend of cases of blood-borne and sexual infectious diseases. This is crucial for the sustainable control of notifiable infectious diseases and the maintenance of social stability. Furthermore, when evaluating the effectiveness of policies (interventions) in the future, it is recommended to adopt an interrupted time series design.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-025-26118-1.Keywords: Notifiable infectious diseases, “Class B infectious disease Class B management” policy, COVID-19, Interrupted time series analysis Background During the COVID-19 pandemic, a variety of non-pharmaceutical interventions (NPIs) were actively pursued around the world to curb the spread of the virus [1–3]. An article published in Nature suggested that as of April 6, 2022, six countries - China, South Korea, Italy, Iran, France and the United States - have averted approximately 495 million total infections by implementing NPIs such as travel restrictions, isolation policies and social distancing [4]. In addition to COVID-19, these NPIs can have a large co-benefit on the prevention of other infectious diseases [5]. Nash et al. found an 81.1% reduction in the incidence of endemic notifiable communicable diseases in England following the introduction of COVID-19 restrictions [6]. Numerous studies have also shown that COVID-19 lockdowns have contributed to reduce reported cases of tuberculosis, AIDS, viral hepatitis, measles and pertussis [7, 8]. Over the past four years (from December 2019 to date), China has continuously adjusted COVID-19 contingency plans based on the evolving situation, successfully preventing the widespread prevalence of more virulent and fatal variants [9]. Given the reduced pathogenicity of the Omicron variant, increased COVID-19 vaccination rates, and enhanced response capacity of the national healthcare system, the novel coronavirus infection has been adjusted from “Class B infectious disease Class A management” to “Class B infectious disease Class B management” on January 8, 2023 [10, 11]. This is a major adjustment to the epidemic policy since the beginning of 2020, when China began to implement strict Class A prevention and control measures. The implementation of the policy aims to enhance the scientific precision of epidemic control, optimize resource allocation efficiency, and achieve better coordination between epidemic containment and socioeconomic development. Simultaneously, the policy sends a clear signal to the international community that China has proactively optimized its prevention and control measures in response to evolving circumstances and scientific considerations. Compared to “Class B infectious disease Class A management”, the “Class B infectious disease Class B management” policy emphasizes that people infected with the novel coronavirus will no longer be quarantined, close contacts will no longer be identified, high or low risk areas will no longer be demarcated, and the testing strategy will be adjusted to “voluntary testing”. This series of relatively relaxed prevention and control measures has led to a surge in the number of novel coronavirus infections [12]. However, to date, it is not clear whether the implementation of the “Class B infectious disease Class B management” policy will have an impact on the spread of other infectious diseases in China. Interrupted time series (ITS) analysis is a quasi-experimental design developed in recent years, which is suitable for quantitative evaluation of the implementation effects of social, environmental and health policies in the absence of valid controls [13–16]. The purpose of this study was to determine whether and to what extent the “Class B infectious disease Class B management” policy has influenced the epidemiological trends in the number of cases and deaths of notifiable infectious diseases in China by using interrupted time series analyses. Methods Data sources Monthly data on cases and deaths of notifiable infectious diseases from December 2019 to May 2024 were obtained from the official website of the National Disease Control and Prevention Administration of the People’s Republic of China (https://www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html) (http://www.nhc.gov.cn/jkj/new_index.shtml). COVID-19 and monkeypox (China has decided to manage monkeypox as a Class B infectious disease starting from September 20, 2023) were excluded from the study. Outcomes There are five common routes of transmission of infectious diseases, namely, contact transmission, airborne transmission, waterborne and foodborne transmission, insect-borne transmission, and blood-borne and sexual transmission. Supplementary Material 1 lists the main transmission routes of the 39 notifiable infectious diseases and their cumulative number of cases and deaths from December 2019 to May 2024. In this study, interrupted time series analyses were performed first on the total number of cases and deaths reported by month for the 39 notifiable infectious diseases, and then on the number of cases and deaths reported by month for those infectious diseases that ranked in the top two in terms of cumulative number of cases and the top one in terms of cumulative number of deaths among each of the five types of transmission routes, so that a total of 17 outcomes of interest were included. Additionally, we conducted interrupted time series analyses on the number of reported cases for the remaining 23 notifiable infectious diseases and the number of reported deaths for the remaining 14 notifiable infectious diseases (diseases with near-zero cases and deaths were excluded), as detailed in the Supplementary Material 2. Intervention The intervention in this study was defined as the implementation of the “Class B infectious disease Class B management” policy. Therefore, we considered two periods during the COVID-19 epidemic: the “Class B infectious disease Class A management” period from December 2019 to December 2022 and the “Class B infectious disease Class B management” period from January 2023 to May 2024. Interrupted time series analysis Interrupted time series analysis can be used to assess the effect of an intervention by comparing the level and slope changes in time series before and after the intervention [17, 18]. Given that the outcome of our study was the number of cases and deaths reported by month, and the large variance of the data led to the problem of overdispersion, a quasi-Poisson regression model was adopted [6, 19]. Since the outbreak of most infectious diseases has obvious seasonality, a Fourier term consisting of two sine/cosine pairs was added to the model to adjust for seasonality [20]. After controlling for seasonality, the autocorrelation problem can often be solved. All analyses were performed using RStudio software (version 4.1.1) together with R packages tsModel and AER. The ITS structure is as follows. : number of cases and deaths of notifiable infectious diseases in month ; : time variable; : pre-intervention = 0 / post-intervention = 1; : time variable after the intervention; : random error; : intercept; : slope before the intervention; : immediate effect of the intervention; : amount of change in slope before and after the intervention, hence the slope for the post-intervention period is ; If P 0.05 and 0, it means that the intervention had a positive immediate effect, and if P 0.05 and 0, it means that the intervention had a positive sustained effect; RR = : assess the relative intensity of the intervention, that is, how many times greater than the original. For example, if = 0.3 and = 0.1, then the RR calculated from indicates that in the month the intervention was implemented, the number of cases immediately rose to 1.35 times the pre-intervention level. The RR calculated from indicates that each subsequent month after the intervention, the number of cases was 1.11 times that of the previous month. Results ITS of the number of reported cases of notifiable infectious diseases 39 notifiable infectious diseases From December 2019 to May 2024, a total of 50,118,811 cases of notifiable infectious diseases (excluding COVID-19 and monkeypox) were reported in China. Since the implementation of the “Class B infectious disease Class B management” policy, the average number of cases per month has increased from 598,104 to 1,646,411. In this study, the ITS method was adopted to predict the total number of cases of the 39 notifiable infectious diseases in China from January 2023 to May 2024 in the absence of the implementation of the “Class B infectious disease Class B management” policy. Counterfactual prediction and parameter estimates showed that (1) the reported number of cases after the intervention increased by 230.69% compared to no intervention; (2) the intervention had a significant positive immediate effect ( = 0.851, RR = 2.342, P = 0.023); and (3) the intervention had no significant sustained effect ( = 0.026, RR = 1.027, P > 0.05) (Fig. 1; Table 1). Trends in the total number of cases of the 39 notifiable infectious diseases. Yellow box represents the time since the implementation of the “Class B infectious disease Class B management” policy Table 1Parameter estimates for the total number of cases of the 39 notifiable infectious diseasesInfectious diseasesParametersEstimated valueSERR(95%CI)P-value39 notifiable infectious diseases -7.7490.263< 0.001(< 0.001–0.001)< 0.001 -0.0030.0120.997(0.973–1.021)0.801 0.8510.3732.342(1.127–4.868)0.023 0.0260.0271.027(0.974–1.082)0.324 Parameter estimates for the total number of cases of the 39 notifiable infectious diseases Notifiable infectious diseases with different transmission routes Counterfactual prediction and parameter estimates for notifiable infectious diseases with different transmission routes showed that (1) compare to no intervention, the reported number of cases of hand, foot and mouth disease increased by 89.02%, influenza by 889.16%, tuberculosis by 21.81%, infectious diarrhea by 34.29%, acute hemorrhagic conjunctivitis by 511.58%, dengue fever by 12,495.57%, malaria by 328.70%, viral hepatitis by 21.53%, and syphilis by 35.41% after the intervention, while brucellosis showed the opposite result, with the number of cases decreasing by 19.92%; (2) For airborne and insect-borne infectious diseases, as well as acute hemorrhagic conjunctivitis, the intervention had a significant positive immediate effect (influenza: = 1.924, RR = 6.850, P = 0.047 / tuberculosis: = 0.170, RR = 1.185, P = 0.010 / dengue fever: = 4.421, RR = 83.202, P < 0.001 / malaria: = 1.108, RR = 3.028, P < 0.001 / acute hemorrhagic conjunctivitis: = 2.269, RR = 9.671, P = 0.001); and (3) For blood-borne and sexual infectious diseases, as well as infectious diarrhea and malaria, the intervention had a significant positive sustained effect (viral hepatitis: = 0.017, RR = 1.017, P = 0.006, the estimated slope after the intervention was = 0.017, and RR() = 1.017, meaning that the number of cases per month after the intervention was about 1.017 times that of the previous month / syphilis: = 0.025, RR = 1.025, P < 0.001, = 0.022, and RR() = 1.022 / infectious diarrhea: = 0.037, RR = 1.037, P = 0.008, = 0.031, and RR() = 1.031 / malaria: = 0.042, RR = 1.043, P = 0.041, = 0.023, and RR() = 1.023) (Fig. 2; Table 2). Trends in the number of cases of infectious diseases with different transmission routes. Yellow box represents the time since the implementation of the “Class B infectious disease Class B management” policy Table 2Parameter estimates for the number of cases of notifiable infectious diseases with different transmission routesInfectious diseasesParametersEstimated valueSERR(95%CI)P-valueContact transmission - Hand, foot and mouth disease -10.0040.268< 0.001(< 0.001-<0.001)< 0.001 -0.0040.0120.996(0.973–1.020)0.748 0.5730.4351.774(0.757–4.160)0.187 0.0140.0381.014(0.940–1.093)0.720Contact transmission - Brucellosis -12.7850.077< 0.001(< 0.001-<0.001)< 0.001 0.0130.0031.013(1.006–1.019)< 0.001 -0.0710.1180.931(0.739–1.175)0.548 -0.0150.0100.985(0.966–1.005)0.143Airborne transmission - Influenza -9.3750.791< 0.001(< 0.001-<0.001)< 0.001 -0.0070.0360.993(0.925–1.066)0.842 1.9240.9696.850(1.025–45.766)0.047 0.0250.0571.025(0.917–1.146)0.660Airborne transmission - Tuberculosis -9.7930.035< 0.001(< 0.001-<0.001)< 0.001 -0.0090.0020.991(0.988–0.995)< 0.001 0.1700.0661.185(1.041–1.349)0.010 0.0010.0061.001(0.990–1.012)0.824Waterborne and foodborne transmission -Infectious diarrhea -9.5030.094< 0.001(< 0.001-<0.001)< 0.001 -0.0060.0040.994(0.985–1.003)0.169 -0.0530.1720.949(0.678–1.328)0.760 0.0370.0141.037(1.010–1.066)0.008Waterborne and foodborne transmission -Acute hemorrhagic conjunctivitis -13.3150.504< 0.001(< 0.001-<0.001)< 0.001 -0.0250.0240.975(0.931–1.022)0.290 2.2690.7009.671(2.454–38.113)0.001 0.0300.0561.031(0.923–1.151)0.589Insect-borne transmission - Dengue fever -17.8210.685< 0.001(< 0.001-<0.001)< 0.001 -0.0540.0330.947(0.888–1.011)0.101 4.4211.07683.202(10.092-685.955)< 0.001 0.0660.0901.069(0.895–1.276)0.463Insect-borne transmission - Malaria -16.3280.174< 0.001(< 0.001-<0.001)< 0.001 -0.0190.0090.981(0.964–0.998)0.026 1.1080.2783.028(1.754–5.226)< 0.001 0.0420.0201.043(1.002–1.085)0.041Blood-borne and sexual transmission -Viral hepatitis -9.3600.044< 0.001(< 0.001-<0.001)< 0.001 < 0.0010.0021.000(0.996–1.004)0.837 0.0340.0751.035(0.893-1.200)0.648 0.0170.0061.017(1.005–1.029)0.006Blood-borne and sexual transmission -Syphilis -10.3320.043< 0.001(< 0.001-<0.001)< 0.001 -0.0030.0020.997(0.993–1.001)0.125 0.0740.0751.077(0.929–1.248)0.327 0.0250.0061.025(1.013–1.037)< 0.001 Parameter estimates for the number of cases of notifiable infectious diseases with different transmission routes Waterborne and foodborne transmission - Infectious diarrhea Waterborne and foodborne transmission - Acute hemorrhagic conjunctivitis Blood-borne and sexual transmission - Viral hepatitis Blood-borne and sexual transmission - Syphilis ITS of the number of reported deaths from notifiable infectious diseases 39 notifiable infectious diseases From December 2019 to May 2024, a total of 110,447 deaths from notifiable infectious diseases (excluding COVID-19 and monkeypox) were reported in China. Since the implementation of the “Class B infectious disease Class B management” policy, the average number of deaths per month has increased from 1,920 to 2,317. We further used the ITS method to predict the total number of deaths from the 39 notifiable infectious diseases in China from January 2023 to May 2024 in the absence of the implementation of “Class B infectious disease Class B management” policy. Counterfactual prediction and parameter estimates showed that (1) the reported number of deaths after the intervention increased by 14.20% compared to no intervention; (2) the intervention had a significant positive immediate effect ( = 0.190, RR = 1.209, P = 0.031); and (3) the intervention had no significant sustained effect ( = -0.009, RR = 0.992, P > 0.05) (Fig. 3; Table 3). Trends in the total number of deaths from the 39 notifiable infectious diseases. Yellow box represents the time since the implementation of the “Class B infectious disease Class B management” policy Table 3Parameter estimates for the total number of deaths from the 39 notifiable infectious diseasesInfectious diseasesParametersEstimated valueSERR(95%CI)P-value39 notifiable infectious diseases -13.5900.053< 0.001(< 0.001-<0.001)< 0.001 0.0040.0021.004(0.999–1.009)0.103 0.1900.0881.209(1.017–1.437)0.031 -0.0090.0070.992(0.977–1.006)0.254 Parameter estimates for the total number of deaths from the 39 notifiable infectious diseases Notifiable infectious diseases with different transmission routes Counterfactual predictions and parameter estimates for notifiable infectious diseases with different transmission routes showed that (1) compare to no intervention, the reported number of deaths from rabies increased by 32.28%, malaria by 325.00%, and acquired immune deficiency syndrome by 13.50% after the intervention, while tuberculosis and infectious diarrhea showed opposite results, with the number of deaths decreasing by 38.67% and 59.36%, respectively; and (2) For tuberculosis, the intervention had a significant negative sustained effect ( = -0.042, RR = 0.959, P = 0.001, the estimated slope after the intervention was = -0.004, and RR() = 0.996, meaning that the number of deaths per month after the intervention was about 0.996 times that of the previous month) (Fig. 4; Table 4). Trends in the number of deaths from infectious diseases with different transmission routes. Yellow box represents the time since the implementation of the “Class B infectious disease Class B management” policy Table 4Parameter estimates for the number of deaths from infectious diseases with different transmission routesInfectious diseasesParametersEstimated valueSERR(95%CI)P-valueContact transmission - Rabies -18.1880.104< 0.001(< 0.001-<0.001)< 0.001 -0.0200.0050.980(0.970–0.990)< 0.001 0.2810.2321.325(0.840–2.088)0.226 0.0020.0201.002(0.963–1.043)0.906Airborne transmission - Tuberculosis -16.5960.122< 0.001(< 0.001-<0.001)< 0.001 0.0380.0051.038(1.028–1.048)< 0.001 -0.0520.1470.949(0.711–1.267)0.724 -0.0420.0120.959(0.936–0.983)0.001Waterborne and foodborne transmission -Infectious diarrhea -20.7510.315< 0.001(< 0.001-<0.001)< 0.001 -0.0490.0180.952(0.919–0.987)0.008 -7.1685.3790.001(< 0.001–29.198)0.183 0.5170.3561.677(0.835–3.367)0.146Insect-borne transmission - Malaria -21.3800.470< 0.001(< 0.001-<0.001)< 0.001 -0.0290.0240.972(0.927–1.018)0.231 1.0710.8482.919(0.553–15.391)0.207 0.0500.0651.051(0.926–1.194)0.443Blood-borne and sexual transmission -Acquired immune deficiency syndrome -13.6940.059< 0.001(< 0.001-<0.001)< 0.001 0.0010.0031.001(0.996–1.006)0.657 0.1880.1021.207(0.989–1.474)0.064 -0.0110.0090.989(0.973–1.006)0.216 Parameter estimates for the number of deaths from infectious diseases with different transmission routes Waterborne and foodborne transmission - Infectious diarrhea Blood-borne and sexual transmission - Acquired immune deficiency syndrome Discussion In the post-COVID-19 era, other notifiable infectious diseases are likely to make a comeback, posing a serious threat to human life, economic, and social development. In this study, we performed a total of 17 interrupted time series analyses to examine the immediate and sustained effects of the “Class B infectious disease Class B management” policy, which was implemented in January 2023, on the number of cases and deaths of notifiable infectious diseases in China. From the perspective of the 39 notifiable infectious diseases, we found that after the implementation of the “Class B infectious disease Class B management” policy, the total number of cases and deaths has increased, with the increase in the total number of cases being very significant. In addition, the total number of cases and deaths was transiently affected by the policy. We believed that there are two reasons for the positive immediate effect. First, after the lifting of strict prevention and control measures against COVID-19, social activities have fully returned to normal, and the transmission chain of infectious diseases has been re-established. Second, the intervention was timed to coincide with winter, when the cold climate is more conducive to the survival and spread of the virus [21]. However, we found no significant sustained effect of the intervention on the total number of cases and deaths. This may be due to the fact that the recovery of the healthcare system in the post-pandemic era has allowed the government to reallocate health and human resources to the prevention and treatment of other infectious diseases, thereby preventing more infections and deaths. From the perspective of infectious diseases with different transmission routes, we found that after the implementation of the “Class B infectious disease Class B management” policy, the number of cases and deaths of most of the infectious diseases has increased, with the increase in the number of cases of dengue fever being extremely significant. The World Health Organization documented that the year 2019 marked an unprecedented peak for dengue fever, with reported instances spreading across 129 countries [22]. Dengue fever epidemics usually happen every three to five years, and in keeping with global trends, the number of dengue fever cases in China reached a four-year high in September 2023. We believed that the high population movements after the policy, the consequences of the El Niño phenomenon in 2023, and the increase in temperature and rainfall due to climate change are the main reasons for the significant increase in dengue fever cases [23]. In addition, a surprising finding of the study was that after the intervention, the number of cases of brucellosis dropped by nearly 20%, and the number of deaths from tuberculosis and infectious diarrhea dropped by nearly 40% and 60% respectively. In 2023, Alxa League, Inner Mongolia conducted a survey on brucellosis, completing blood tests for 4,425 individuals to achieve early detection and prompt intervention. In 2023, the brucellosis prevention and control work in Alxa League achieved remarkable results, with the number of cases decreasing by 21.62% compared to 2022 [24]. During the period of “Class B infectious disease Class A management”, strict lockdown measures brought about a series of serious problems, such as the weakening of tuberculosis control programme, insufficient supply of anti-tuberculosis drugs (significantly reduced drug accessibility), and patients being unable to attend hospitals on schedule to collect their medication. Furthermore, as the majority of healthcare resources were tilted towards COVID-19, the diagnosis and treatment of tuberculosis were delayed. Since the implementation of the “Class B infectious disease Class B management” policy, the lockdown areas have been lifted and medical resources have been progressively channeled to tuberculosis, resulting in a significant long-term decline in the number of tuberculosis deaths. By the end of 2022, 40 countries around the world have started using six-month BPaLM/BPaL regimens for the treatment of multidrug- and rifampicin-resistant tuberculosis [25]. As of September 2023, 28 tuberculosis treatment drugs are in Phase I, II or III trials, and two have received drug regulatory approval, providing a significant contribution to improving tuberculosis treatment outcomes [26]. Data from the National Health Commission of the People’s Republic of China showed that the central financial special fund of tuberculosis prevention and treatment has increased year by year, from 560 million yuan in 2011 to 1.14 billion yuan in 2022, especially for drug-resistant tuberculosis treatment and laboratory capacity building. Despite the continuous increase in medical resources allocated to tuberculosis treatment since the implementation of the “Class B infectious disease Class B management” policy, the intervention had not produced a significant immediate effect, owing to the treatment cycle requiring a minimum of four months [27]. In the post-COVID-19 era, there has been a marked increase in the number of people proactively seeking vaccination, especially in vulnerable groups of children, and rotavirus vaccination is the most cost-effective and efficient means of reducing the risk of death from infectious diarrhea [28, 29]. The above points provided strong evidence for reversing and eliminating the negative impact of the epidemic on brucellosis cases and tuberculosis and infectious diarrhea deaths after 2023. In terms of immediate effects, the implementation of the “Class B infectious disease Class B management” policy had a significant positive immediate effect on the number of cases of airborne and insect-borne infectious diseases. Sarvepalli et al. found that the incidence of influenza A and B in the 2020–2021 season affected by the COVID-19 pandemic decreased significantly compared to the 2019–2020 season in both the pediatric and adult populations [30]. There is therefore reason to believe that the sudden liberalization of COVID-19 could lead to an immediate rise in the number of cases of airborne infectious diseases. Consistent with our findings, both the USA and England experienced an immediate significant increase in influenza cases after the removal of restrictions [31]. Another study showed that in residential buildings, efforts to reduce the risk of COVID-19 by increasing circulation of indoor air may increase exposure to mosquitoes [32]. With the promulgation of the “Class B infectious disease Class B management” policy, the majority of residents in China opted for home isolation. Residents usually opened windows for ventilation, which is an effective way to dilute and expel any viral aerosols that may be present in indoor air. However, this practice inevitably involved contact with mosquitoes, thereby increasing the risk of transmission of dengue fever or malaria. In conclusion, if China or other regions relax their prevention and control measures against coronavirus infectious diseases similar to SARS in the future, our findings will prompt health authorities to pay timely attention to the trend of cases of airborne and insect-borne infectious diseases. For example, ensuring timely influenza vaccination and avoiding outdoor activities during the active mosquito season. In terms of sustained effects, the implementation of the “Class B infectious disease Class B management” policy had a significant positive sustained effect on the number of cases of blood-borne and sexual infectious disease, while had a significant negative sustained effect on the number of deaths from tuberculosis. A survey showed that 44% of participants reported a decrease in the number of sexual partners during the COVID-19 lockdown [33], and that the increase in sexual activity in these groups after liberalization is likely to increase the transmission risk of blood-borne and sexual infectious diseases such as hepatitis B and syphilis. In addition, the decline in vigilance (low condom use rate) is also an important factor contributing to the resurgence of blood-borne and sexual infectious diseases [34]. Since the fully liberalization of COVID-19 in 2023, 400 districts in China have launched tuberculosis-free community campaigns and established a comprehensive tuberculosis surveillance network for case detection, reporting, referral, treatment and follow-up. Moreover, technological advances such as AI-assisted reading of chest radiographs, second-line molecular drug sensitivity rapid testing equipment, and China’s RR-TB all-oral ultra-short-course regimen have broken through the bottleneck of tuberculosis prevention and treatment and contributed greatly to the sustained reduction of tuberculosis deaths in recent years [35]. On March 9, 2024, the National Disease Control and Prevention Administration stated that the mortality rate of tuberculosis in China had fallen to the level of developed countries, indicating that China’s tuberculosis control efforts have made great strides. In conclusion, if China or other regions relax their prevention and control measures against coronavirus infectious diseases similar to SARS in the future, our findings will prompt health authorities to pay close attention to the trend of cases of blood-borne and sexual infectious diseases in the long term. For example, increasing hepatitis B vaccination coverage, maximizing the detection of hepatitis virus carriers in the population, and expanding the use of PrEP among high-risk groups for HIV. Admittedly, this study has some limitations. First, the COVID-19 pandemic inevitably led to underdiagnosis and delayed diagnosis of other infectious diseases, so the number of reported cases and deaths may be lower than the actual values. Secondly, we conducted interrupted time series analyses based on national-level data from a macro perspective. As regional data (east/central/west and urban/rural) is currently unavailable, we have not yet compared whether there are differences in the immediate and sustained effects of the intervention among different regions. In the future, if data becomes available, we will consider the actual development of the epidemic and the implementation intensity of prevention and control measures in each region to conduct more detailed interrupted time series analyses. Finally, interrupted time series analysis is a quasi-experimental design with weaker causal inference than a randomized controlled trial, making it difficult to infer that there is a causal relationship between the implementation of the “Class B infectious disease Class B management” policy and the increase in the number of cases and deaths of other notifiable infectious diseases. Conclusions To our knowledge, this is the first study to use interrupted time series analyses to explore the impact of the implementation of the “Class B infectious disease Class B management” policy on the number of cases and deaths of notifiable infectious diseases in China. In the post-COVID-19 era, timely catch-up vaccination is needed, such as influenza and hepatitis B vaccines, based on the implementation of non-pharmaceutical and pharmaceutical interventions. If the prevention and control measures against coronavirus infectious diseases similar to SARS are relaxed in the future, health authorities need to be vigilant in a timely manner to prevent a sudden increase in the number of cases of airborne and insect-borne infectious diseases, and to store medical resources and anti-epidemic supplies for blood-borne and sexual infectious diseases for a long time, which is essential for the sustainable control of notifiable infectious diseases and the prevention of resurgence of outbreaks. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Acknowledgements The authors would like to thank the study members for collecting such valuable data. The authors also thank the anonymous reviewers for their valuable suggestions. Author contributions J.X. and H.Y. conceived and designed the study. Y.L., J.L., L.L., L.H., and T.W. collected and curated the data. Y.M., S.X., Y.N., and J.G. contributed to model development. Y.M. and S.X. analyzed the data. Y.M. wrote the manuscript. All authors reviewed the manuscript. Funding This work was supported by the Major Science and Technology Special Project for Prevention and Control of Emerging and Re-emerging Major Infectious Diseases (2025ZD01902102), the Major Science and Technology Project of Shanxi Province (202102130501003, 202005D121008), the Special Foundation on COVID-19 of Shanxi Health Commission (16), and the Graduate Education Innovation Project of Shanxi Province (2023KY363). Data availability The program code is available in the Supplementary Material 3, and the dataset analyzed during the current study is available in the Supplementary Material 4. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hongmei Yu, Email: yu@sxmu.edu.cn. Jun Xie, Email: junxiesxmu@163.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Data Availability Statement The program code is available in the Supplementary Material 3, and the dataset analyzed during the current study is available in the Supplementary Material 4.